Dyax Corp. Company Profile
Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Our lead product, DX-88, has been approved under the brand name KALBITOR® (ecallantide) in the United States for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.
News Articles
Dyax, FivePrime Cut Antibody Deal
Cambridge, MA-based Dyax (NASDAQ: DYAX) and South San Francisco-based FivePrime Therapeutics said today they have agreed to collaborate on an effort to discover new antibody drugs. Dyax will use its p...
Dyax licenses preclinical cancer compound to Kadmon
Dyax Corp. (NASDAQ:DYAX) granted Kadmon Corp. LLC (New York, N.Y.) exclusive, worldwide rights to develop and commercialize preclinical cancer compound DX-2400. Dyax will receive an undisclosed upfron...
Dyax And ViroPharma: An Overview Of HAE Space
By LifeSci Advisors:By Leyi Wang, Ning Yang, Ph.D., and Andrew McDonald, Ph.D.Dyax Corp. (DYAX) is a biopharmaceutical company that uses its proprietary phage display technology to discover novel ther...
Dyax planning $30 million offering
Dyax Corp. (NASDAQ:DYAX) proposed to raise about $30 million through the sale of 8.9 million common shares at $2.30 and 42,418 shares of series 1 convertible preferred shares at $230 in a registered d...
Dyax Announces Extension of Partnership with Bayer for Access to Dyaxs Fully-Human Antibody ...
Dyax extends antibody phage display library partnership with Bayer
Based on successful antibody discovery work during a research evaluation period, Bayer Pharma AG has executed a licence to Dyax Coporation’s antibody phage display technology for development and pot...
Dyax partners with CVie Therapeutics for Kalbitor in Greater China
US drug developer Dyax Corp (Nasdaq: DYAX) yesterday announced a strategic partnership with CVie Therapeutics, a subsidiary of Lee's Pharmaceutical Holdings, for the development and commercialization...
Dyax Corporation's CEO Presents at UBS Global Life Sciences Conference (Transcript)
Dyax Corporation (DYAX) UBS Global Life Sciences Conference Call September 20, 2012, 09:00 am ET Executives Gustav Christensen - President & CEO Analysts Presentation Unidentified...
Drugs and Medications
These highlights do not include all the information needed to use KALBITOR safely and effectively. See full prescribing information for KALBITOR. KALBITOR (ecallantide) Injection for subcutaneous use...
PubMed Articles
None
Clinical Trials
None
Companies
Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs. Dyax utilizes its propri...
Dyax is developing and commercializing new products for the pharmaceutical and biopharmaceutical industries. We discover and develop products using Dyax's two technology platforms: Phage Display B...
Zenyth Therapeutics Limited (Zenyth) is a public listed (ASX: ZTL) Australian biotechnology company primarily focused on the development and commercialisation of antibody-based therapies in the areas...
BioCatalyst is a group of experienced business and scientific entrepreneurs who are focused on transitioning a scientifically validated product to an accepted product in the marketplace. BioCatalyst i...
More Information about "Dyax Corp." on BioPortfolio
We have published hundreds of Dyax Corp. news stories on BioPortfolio along with dozens of Dyax Corp. Clinical Trials and PubMed Articles about Dyax Corp. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Dyax Corp. Companies in our database. You can also find out about relevant Dyax Corp. Drugs and Medications on this site too.
